Overview
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Eligibility
Inclusion Criteria:
- Aged ≥18 and older
- Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
- HR+/HER2-
- ECOG 0-3
- Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors
Exclusion Criteria:
- During pregnancy or lactation
- Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption